KR20120128644A - 질환의 치료에 사용하기 위한 화합물 - Google Patents

질환의 치료에 사용하기 위한 화합물 Download PDF

Info

Publication number
KR20120128644A
KR20120128644A KR1020127022355A KR20127022355A KR20120128644A KR 20120128644 A KR20120128644 A KR 20120128644A KR 1020127022355 A KR1020127022355 A KR 1020127022355A KR 20127022355 A KR20127022355 A KR 20127022355A KR 20120128644 A KR20120128644 A KR 20120128644A
Authority
KR
South Korea
Prior art keywords
compound
disease
hydrazide
epo
phenylaminoethane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127022355A
Other languages
English (en)
Korean (ko)
Inventor
안드레아스 쿠빈
파울 퓌르트뮐러
게르하르트 볼버
다니엘라 슈스터
Original Assignee
이노시아 라이프사이언스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이노시아 라이프사이언스 게엠베하 filed Critical 이노시아 라이프사이언스 게엠베하
Publication of KR20120128644A publication Critical patent/KR20120128644A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020127022355A 2010-01-29 2011-01-28 질환의 치료에 사용하기 위한 화합물 Ceased KR20120128644A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0012210A AT509045B1 (de) 2010-01-29 2010-01-29 Verbindungen zur behandlung von asthma bronchiale
ATA122/2010 2010-01-29
PCT/AT2011/000050 WO2011091461A1 (de) 2010-01-29 2011-01-28 Verbindungen zur verwendung bei der behandlung von erkrankungen

Publications (1)

Publication Number Publication Date
KR20120128644A true KR20120128644A (ko) 2012-11-27

Family

ID=43707937

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127022355A Ceased KR20120128644A (ko) 2010-01-29 2011-01-28 질환의 치료에 사용하기 위한 화합물

Country Status (12)

Country Link
US (1) US20130065962A1 (enExample)
EP (2) EP2965755A1 (enExample)
JP (1) JP5788907B2 (enExample)
KR (1) KR20120128644A (enExample)
CN (2) CN104958286B (enExample)
AT (1) AT509045B1 (enExample)
AU (1) AU2011208939B2 (enExample)
BR (1) BR112012018772A2 (enExample)
CA (1) CA2788326A1 (enExample)
MX (1) MX2012008815A (enExample)
SG (1) SG182786A1 (enExample)
WO (1) WO2011091461A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013302177A1 (en) * 2012-08-10 2015-03-26 Mcmaster University Antibacterial inhibitors
TWI689490B (zh) * 2013-03-15 2020-04-01 英商邊緣生物科技有限公司 用於治療纖維化之經取代之芳族化合物及相關方法
SG11201702812PA (en) * 2014-10-10 2017-05-30 Prometic Pharma Smt Ltd Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes
EP3323428A1 (en) * 2016-11-17 2018-05-23 CNRS Centre National de la Recherche Scientifique Selective c-flip inhibitors as anticancer agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082846A (en) 1976-11-18 1978-04-04 University Of Utah Method for treating psoriasis
JPH02753A (ja) * 1987-12-24 1990-01-05 Ono Pharmaceut Co Ltd カルバゾイル誘導体、それらの製造方法およびそれらを有効成分として含有するメイラード反応阻害剤
EP0323590A3 (en) 1987-12-24 1990-05-02 Ono Pharmaceutical Co., Ltd. Carbazoyl derivatives
WO1992017065A2 (en) 1991-04-01 1992-10-15 Duke University Method of inhibiting fibrosis
US5324747A (en) * 1992-07-15 1994-06-28 Hoffmann-La Roche Inc. N-substituted anilines, inhibitors of phospholipases A2
CH683965A5 (it) * 1993-02-19 1994-06-30 Limad Marketing Exp & Imp Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici.
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
US6197743B1 (en) * 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
US5741926A (en) * 1997-02-12 1998-04-21 Shaman Pharmaceuticals, Inc. Aniline derivatives having antihyperglycemic activity
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
CA2324426A1 (en) * 1998-02-11 1999-08-19 Douglas V. Faller Compositions and methods for the treatment of cystic fibrosis
WO2000015215A1 (en) * 1998-09-15 2000-03-23 Korea Research Institute Of Bioscience And Biotechnology Composition containing cinnamic acid derivatives for preventing or treating elevated blood lipid level-related diseases
AU2004242565A1 (en) * 1999-01-12 2005-01-27 Kenneth Blum Treatment of hypertension with compounds that inhibit the destruction of enkephalins or endorphins
US6610715B1 (en) 1999-05-28 2003-08-26 Cheil Jedang Corporation Cathecol hydrazone derivatives, process for preparing the same and pharmaceutical composition containing the same
IT1313567B1 (it) * 1999-07-27 2002-09-09 Zambon Spa Uso della n-acetil-cisteina per la preparazione di composizionifarmaceutiche topiche per il trattamento di patologie allergiche delle
US6444829B1 (en) 2000-07-19 2002-09-03 Hoffmann-La Roche Inc. Pyrrolidine compounds
WO2003084940A1 (en) 2002-04-08 2003-10-16 Alangudi Sankaranarayanan Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
US7741352B2 (en) 2003-03-11 2010-06-22 Neurosearch A/S KCNQ channel modulating compounds and their pharmaceutical use
WO2005085185A1 (en) 2004-03-03 2005-09-15 Smithkline Beecham Corporation Aniline derivatives as selective androgen receptor modulators
DE102004028862A1 (de) 2004-06-15 2005-12-29 Merck Patent Gmbh 3-Aminoindazole
CN1686297A (zh) * 2005-04-07 2005-10-26 甘肃圣达医药科技有限责任公司 一种止咳平喘药物及其制备方法
CU23431B6 (es) * 2005-05-12 2009-10-16 Ct Ingenieria Genetica Biotech Método para la inhibición de la proliferación de células tumorales y el tratamiento del cáncer
WO2007026215A1 (en) 2005-08-29 2007-03-08 Glenmark Pharmaceuticals S.A. Pyrazole derivatives as cannabinoid receptor ligands, pharmaceutical compositions containing? them, and processes for their preparation
DE102006005179A1 (de) 2006-02-06 2007-08-09 Merck Patent Gmbh Aminoindazolderivate
PT2061765E (pt) * 2006-09-01 2015-02-06 Senhwa Biosciences Inc Moduladores de serina-treonina-proteína-quinase e de parp
BRPI0809974A2 (pt) 2007-03-30 2014-10-07 Sanofi Aventis Compostos de pirimidina hidrazida como inibidores de pgds
TWI490214B (zh) 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途
TWI485134B (zh) * 2009-05-04 2015-05-21 波麥堤克生化科學公司 取代的芳族化合物及其藥學用途

Also Published As

Publication number Publication date
US20130065962A1 (en) 2013-03-14
EP2528595B1 (de) 2015-08-05
AU2011208939B2 (en) 2015-07-09
CA2788326A1 (en) 2011-08-04
SG182786A1 (en) 2012-09-27
CN102858329A (zh) 2013-01-02
JP5788907B2 (ja) 2015-10-07
JP2013518061A (ja) 2013-05-20
CN104958286B (zh) 2018-01-05
BR112012018772A2 (pt) 2016-04-12
AU2011208939A1 (en) 2012-08-30
MX2012008815A (es) 2012-11-23
CN102858329B (zh) 2015-06-17
AT509045B1 (de) 2011-06-15
CN104958286A (zh) 2015-10-07
AT509045A4 (de) 2011-06-15
WO2011091461A1 (de) 2011-08-04
EP2528595A1 (de) 2012-12-05
EP2965755A1 (de) 2016-01-13

Similar Documents

Publication Publication Date Title
JP2004525179A (ja) ジペプチジルペプチダーゼｉｖ阻害剤でのｉｉ型糖尿病の処置
US20220001014A1 (en) Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
US20200055926A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
NO20076245L (no) Anvendelse av TFPI for a behandle alvorlige bakterieinfeksjoner
EP1369119B1 (en) Il-12 expression controlling agents
US8410068B2 (en) Compounds for the treatment or alleviation of edema, and methods for their use
EP3193907A1 (en) Method of treating prader-willi syndrome
CA3212316A1 (en) Treatment of hidradenitis suppurativa with orismilast
Nobile et al. Could the antipsychotic chlorpromazine be a potential treatment for SARS-CoV-2?
KR20120128644A (ko) 질환의 치료에 사용하기 위한 화합물
US20230210807A1 (en) Use of benzoate compound in treatment of sars-cov-2 infections
CA2334990A1 (fr) Nouvelle utilisation de composes inhibiteurs de la protease du vih
Devaraj et al. Interaction between warfarin and topical miconazole cream
JP2014521740A (ja) Ｃｙｐ４ａ阻害剤を有効成分として含有する糖尿病又は脂肪肝の予防又は治療用薬学的組成物。
MD4802C1 (ro) Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor
US20180271944A1 (en) Methods for treating diseases mediated by erbb4-positive pro-inflammatory macrophages
KR20220084122A (ko) 패혈증 및 패혈증 유사 증상의 조기 관리 및 예방
WO2020029441A1 (zh) 尼克酰胺组合物在制备治疗索拉非尼手足皮肤反应药物中的应用
WO2023203022A1 (en) Treatment of neutrophilic dermatoses
Chen et al. Oseltamivir Phosphate Modulates CD24‐Siglec‐G/10 Interaction to Suppress Microglial‐Driven Neuroinflammation After Cardiac Arrest
KR101606885B1 (ko) 아데닌 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 알레르기 질환 예방 및 치료용 약학적 조성물
CN110496128B (zh) 利培酮或帕潘立酮在制备治疗弥漫性大b细胞淋巴瘤的药物中的应用
Feijoo et al. AB0363 safety of jak inhibitors in patients with arthritis rheumatoid under real-life conditions
WO2022157676A1 (en) Edta and egta for use in preserving the integrity of therapeutic compounds
WO2021012694A1 (zh) 乙基甲基羟基吡啶苹果酸盐或其药物组合物，预防和/或治疗ⅱ型糖尿病的用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20160112

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170501

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20171106

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170501

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I